In addition, the combination of nofazinlimab and an anti-CTLA-4 antibody was explored in one phase 1a/1b study (NCT03523819); this combination demonstrated an encouraging anti-tumor activity and favorable safety profile in patients with MSI-H/dMMR tumors, anti-PD-(L)1-refractory melanoma and anti-PD-(L)1-refractory hepatocellular carcinoma [42, 43]. This evidence concerns the gene CTLA4 and melanoma.